Open Access
Infantile haemangioma: a complicated disease
Mingke Qiu1,Xianqin Qi1,Yuxin Dai1,Shuqing Wang1,Zhiwei Quan1,Yingbin Liu1,Jingmin Ou1,*
Department of General Surgery, Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai China
DOI: 10.2741/4353 Volume 20 Issue 7, pp.1004-1016
Published: 01 June 2015
(This article belongs to the Special Issue Pathogenesis and diagnostic modalities in cancer)
*Corresponding Author(s):  
Jingmin Ou

Infantile haemangiomas (IH) are common benign vascular tumors of childhood. They are characterised by rapid growth during the first year of life and slow regression that is usually completed by 7–10 years of age. The underlying mechanism of action of IH is aberrant angiogenesis and vasculogenesis, and involves the mammalian target of rapamycin pathway and vascular endothelial growth factor pathway. IH become a challenge if they are part of a syndrome, are located in certain areas of the body, or if complications develop. The beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. This review focuses on the clinical characteristics, pathogenesis and management of IH.

Key words
Infantile Haemangioma,Benign Vascular Tumor,Clinical Treatment,Review
Share and Cite
Mingke Qiu, Xianqin Qi, Yuxin Dai, Shuqing Wang, Zhiwei Quan, Yingbin Liu, Jingmin Ou. Infantile haemangioma: a complicated disease. Frontiers in Bioscience-Landmark. 2015. 20(7); 1004-1016.